Research interest in retatrutide among UAE-based investigators has accelerated sharply since the Jastreboff 2023 data landed. The molecule is not simply another GLP-1 analog — it is a structurally distinct triagonist whose glucagon receptor co-activity separates it mechanistically from semaglutide, tirzepatide, and anything previously seen in clinical peptide research. For investigators running structured protocols, the titration schedule is not cosmetic: it is the difference between interpretable data and dropout from GI intolerance. The 4mg titration week sits at a pharmacologically important inflection point, and understanding the rationale makes the protocol design defensible. REVIVE LAB UAE supplies HPLC-verified, lot-COA, cold-chain dispatched retatrutide across all 7 emirates for researchers who need consistent, traceable supply.
Retatrutide (LY3437943) is a long-acting, acylated peptide designed to co-agonize three G-protein-coupled receptors simultaneously: the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR). This triagonist architecture is the defining mechanistic feature that distinguishes retatrutide from its predecessors in the incretin class.
The fatty acid acylation on the retatrutide peptide backbone extends the half-life to approximately one week via albumin binding, which is why the research protocol uses once-weekly subcutaneous administration rather than the daily dosing common with shorter peptides. This weekly dosing rhythm is also what makes the vial math straightforward for researchers working with REVIVE LAB UAE 5mg or 10mg stock.
The Jastreboff et al. 2023 Phase 2 trial used a structured, blinded dose-escalation design with participants randomized across four once-weekly dose arms (1mg, 4mg, 8mg, and 12mg) plus placebo, over 24 weeks, with a 48-week extension for the highest-dose cohort. Critically, none of the arms started at their target dose. Investigators designed a slow titration ramp to permit gastrointestinal accommodation — the same rationale used with tirzepatide and semaglutide, and a protocol feature that research teams replicating this design should treat as essential, not optional.
The general research-context titration structure that emerges from the published methods is:
The opening 2mg weekly dose is primarily a GI-tolerance establishment phase. At this step, GLP-1R signaling dominates the acute response — gastric emptying slows, appetite signals shift. GCGR co-activity at 2mg is present but relatively modest. Investigators in the Jastreboff trial documented GI adverse events (nausea, reduced appetite) clustered in the early weeks, with incidence declining as duration lengthened — the classic accommodation signature of GLP-1R-class agonists. Research teams using a 4-week 2mg phase before stepping up are following the conservative design that minimised dropout in the published trial.
The 4mg step is where the research begins in earnest. By week 5, GI accommodation is typically established and all three receptor targets — GIPR, GLP-1R, GCGR — are engaged at levels that produce meaningful metabolic signal. This is the step the Jastreboff 2023 participants in the 8mg and 12mg arms passed through before their final escalation, and it is the dose level closest to the original 4mg fixed-dose arm (which showed a −8.7% body-weight reduction at 24 weeks in the trial). For research teams whose protocol calls for a 4mg maintenance phase rather than further escalation, this is also the endpoint dose — supported by its own data cohort in the published literature.
The mechanism logic at 4mg: GLP-1R saturation is near-complete, GIPR co-agonism is fully engaged, and the GCGR contribution to elevated energy expenditure and hepatic lipid mobilization is measurable. Rosenstock et al. 2023 (Lancet), studying retatrutide in participants with type 2 diabetes, found that the 4mg dose significantly improved HbA1c versus placebo while simultaneously reducing body weight — confirming that the glycaemic and metabolic profiles operate concurrently even at this mid-range dose, not sequentially.
The 8mg step represents the upper mid-tier of the triagonist's dose range in the published data. The Jastreboff 8mg arm produced approximately −17.3% body-weight reduction at 24 weeks, while the 12mg arm reached −24.2% at 48 weeks. Investigators designing escalation-to-8mg protocols should budget for a minimum 4-week 4mg consolidation phase before stepping up, mirroring the trial's rationale of tolerance before target dose. For most UAE-based research teams, a 5mg vial from REVIVE LAB UAE covers one escalation week at the 4mg step with a precisely measured draw, or two starting weeks at 2mg.
The Jastreboff et al. 2023 NEJM Phase 2 trial (the TRIPLE-PHARMACOLOGY study, n=338 adults with obesity, BMI ≥30 kg/m², 24-week primary endpoint with 48-week extension) is the anchor citation for any retatrutide research protocol. Key data points relevant to titration design:
| Arm (Once-Weekly SC) | Mean Body-Weight Change at 24 Wks | 48-Week Data | GI AE Incidence (Any) |
|---|---|---|---|
| Placebo | −2.1% | N/A | 26% |
| 1 mg | −7.9% | — | 44% |
| 4 mg | −8.7% | — | 62% |
| 8 mg | −17.3% | — | 67% |
| 12 mg | −22.8% | −24.2% | 71% |
The GI adverse event incidence climbing from 44% to 71% across the dose range underscores why the titration ladder matters. The trial protocol was not designed to reach 12mg at week one — and research teams who attempt to shortcut the ramp will encounter the same dose-limiting tolerability issues the trial documented at higher doses without prior accommodation.
Rosenstock et al. 2023 (Lancet) adds the T2D dimension: in a population with established type 2 diabetes, retatrutide doses from 0.5mg to 12mg once weekly produced dose-dependent HbA1c reductions of up to −2.02 percentage points at 36 weeks, alongside significant body-weight effects. The 4mg dose was again a consistent inflection point: clinically meaningful glycaemic impact with a more manageable tolerability profile than the highest arms.
REVIVE LAB UAE stocks retatrutide in two vial sizes: 5mg and 10mg. Both are lyophilized (freeze-dried) for stability. The reconstitution target concentration depends on the dose step being investigated. The most practical working concentration for the 2mg–4mg–8mg titration ladder is 2mg/mL — it keeps draw volumes in a manageable range across all steps.
| Vial Size | BAC Water Added | Working Concentration | Volume per Dose Step |
|---|---|---|---|
| Retatrutide 5 mg | 2.5 mL | 2 mg/mL | 2mg = 1.0 mL | 4mg = 2.0 mL |
| Retatrutide 10 mg | 5.0 mL | 2 mg/mL | 2mg = 1.0 mL | 4mg = 2.0 mL | 8mg = 4.0 mL |
| Retatrutide 10 mg | 2.0 mL | 5 mg/mL | 2mg = 0.4 mL | 4mg = 0.8 mL | 8mg = 1.6 mL |
For once-weekly SC protocols, the 5mg/mL concentration (10mg vial + 2mL BAC water) is convenient because the draw volumes are small enough for a standard 1mL insulin syringe at every step. Always reconstitute by directing the BAC water stream slowly down the inner glass wall — never directly onto the lyophilized cake — and allow 2-3 minutes for the cake to dissolve without shaking. Reconstituted vials should be stored at 2-8°C and, per standard peptide research protocols, used within 14 days. Since retatrutide is dosed once weekly, a reconstituted 10mg vial supports two weeks of a 4mg research protocol, or a 2mg/4mg split across back-to-back escalation weeks.
Researchers in the UAE have a narrow field of credible suppliers for retatrutide. The compound is a high-value, precision peptide — purity documentation, cold-chain integrity, and lot traceability are non-negotiable for research-grade sourcing. REVIVE LAB UAE is the UAE-based peptides supplier that covers all of these bases: HPLC purity verification (≥99%), lot-specific COA available on request, and refrigerated courier dispatch from Dubai across all seven emirates.
Whether you need retatrutide same day Dubai for a protocol starting this week, or retatrutide Dubai 24h delivery to Abu Dhabi, Sharjah, RAK, or Fujairah, REVIVE LAB UAE has the logistics wired. Cash on delivery is the default payment method across the UAE. USDT crypto payment is also accepted via Binance Pay — a 5% pre-pay discount applies. For researchers comparing suppliers on cost, the ability to receive cold-chain dispatched, COA-backed retatrutide in stock UAE without waiting on international freight is the operational advantage.
| Emirate / Zone | Delivery Window | Cash on Delivery | Cold-Chain Packaging |
|---|---|---|---|
| Dubai (Marina, JBR, Business Bay, DIFC, JVC, Palm, Downtown, Jumeirah) | Same-day, 4–8 hours | Yes | Yes |
| Abu Dhabi (Corniche, Yas Island, Saadiyat, Reem Island, Al Ain) | Next-day, 18–24 hours | Yes | Yes |
| Sharjah | Same-day / next-day, 8–18 hours | Yes | Yes |
| Ajman | Next-day, 18–24 hours | Yes | Yes |
| Ras Al Khaimah (RAK) | Next-day, 18–24 hours | Yes | Yes |
| Fujairah | Next-day, 24 hours | Yes | Yes |
| Umm Al Quwain (UAQ) | Next-day, 18–24 hours | Yes | Yes |
There is a meaningful difference between a peptides UAE storefront that resells unverified offshore material and a supplier with actual quality infrastructure. REVIVE LAB UAE is built around the latter: every retatrutide batch is HPLC-tested for purity and identity before dispatch, a lot-specific COA is available for every order, and vials are dispatched in validated cold-chain insulation that holds 2–8°C through UAE summer ambient temperatures. Retatrutide is not a forgiving molecule if the cold chain breaks — unlike some lyophilized peptides, its acylated structure is particularly sensitive to degradation once exposed to heat post-reconstitution. The courier network REVIVE LAB UAE runs for retatrutide same day Dubai was designed for this requirement specifically.
For investigators running the complete 2mg → 4mg → 8mg escalation protocol, REVIVE LAB UAE's 10mg vial is the most supply-efficient format: a single vial reconstituted at 2mg/mL covers four weeks of once-weekly dosing across the 2mg and 4mg steps. The 5mg vial is the right choice for researchers who want to run a single escalation week or evaluate the 4mg step as a fixed-dose protocol arm. Both sizes ship across all seven emirates with the same lot-COA and cold-chain standard. For the full REVIVE LAB UAE peptides catalogue — including Tesamorelin, GHK-Cu, BPC-157, TB-500, Semax, and MOTS-c — see the products page.
REVIVE LAB UAE stocks retatrutide 5mg and 10mg vials with HPLC verification, lot-COA documentation, and cold-chain dispatch. Researchers based in Dubai — including Dubai Marina, JBR, Business Bay, DIFC, JVC, Palm Jumeirah, Downtown, and Jumeirah — receive same-day delivery within 4–8 hours. All other emirates receive next-day delivery within 24 hours. Cash on delivery is supported across all seven emirates, and USDT crypto payment via Binance Pay is accepted for a 5% pre-pay discount. This is what retatrutide in stock UAE with genuine local logistics looks like.
REVIVE LAB UAE stocks retatrutide in 5mg and 10mg vials only — these are the two stocked strengths. For a research-context 2mg/mL working solution, add 2.5mL bacteriostatic water to a 5mg vial (1mL draw = 2mg; 2mL draw = 4mg) or 5mL BAC water to a 10mg vial (1mL = 2mg; 2mL = 4mg; 4mL = 8mg). For a more concentrated 5mg/mL solution, add 2mL BAC water to the 10mg vial and work with smaller draw volumes: 0.4mL = 2mg; 0.8mL = 4mg; 1.6mL = 8mg. No other vial strengths are stocked.
In the Jastreboff et al. 2023 NEJM Phase 2 trial, the 4mg step is the mid-escalation checkpoint — typically weeks 5–8 of the titration ladder — between the 2mg introductory dose and the 8mg maintenance or escalation step. At 4mg, all three receptor targets of the triagonist (GLP-1R, GIPR, GCGR) are meaningfully engaged. The published 4mg fixed-dose arm showed −8.7% body-weight reduction at 24 weeks as a standalone dose, making it both an escalation waypoint and a valid research target in its own right. Rosenstock et al. 2023 (Lancet) further confirmed robust glycaemic effects at this dose level in a T2D population.